Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR119 | Q8TDV5 | 15/20 | 0.52 |
| ▸ | CHRM4 | P08173 | 3/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.48 |
| ▸ | LMNA | P02545 | 1/20 | 0.48 |
| ▸ | MAPT | P10636 | 1/20 | 0.48 |
| ▸ | TGFBR1 | P36897 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6156057 | 0.89 | GPR119 (0.67) | GPR119CHRM4TGFBR1 | |
| SCHEMBL4509519 | 0.86 | GPR119 (0.58) | GPR119TGFBR1 | |
| SCHEMBL13587106 | 0.85 | MAPT (0.63) | GPR119ALDH1A1LMNAMAPT | |
| SCHEMBL6152361 | 0.83 | CHRM4 (0.51) | CHRM4LMNAMAPT | |
| SCHEMBL8126900 | 0.82 | GPR119 (0.56) | GPR119ALDH1A1LMNAMAPT | |
| SCHEMBL6793394 | 0.82 | RECQL (0.60) | GPR119ALDH1A1LMNAMAPT | |
| SCHEMBL18822190 | 0.81 | GPR119 (0.48) | GPR119ALDH1A1LMNAMAPTTGFBR1 | |
| SCHEMBL18788038 | 0.81 | GPR119 (0.48) | GPR119ALDH1A1LMNAMAPTTGFBR1 | |
| SCHEMBL5237966 | 0.80 | MAPT (0.57) | GPR119ALDH1A1LMNAMAPT | |
| SCHEMBL6156540 | 0.80 | GPR119 (0.53) | GPR119 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050143391-A1 | Heterocyclic amides with alpha-4 integrin antagonist activity | J. Uriach Y Compañia S.A. (ES) | 2005-06-30 | — | — | US | disclosed |
| EP-1495044-A1 | HETEROCYCLIC AMIDES WITH ALPHA-4 INTEGRIN ANTAGONIST ACTIVITY | J. Uriach y Compania S.A. (ES) | 2005-01-12 | — | — | EP | disclosed |
| WO-2003084984-A1 | HETEROCYCLIC AMIDES WITH ALPHA-4 INTEGRIN ANTAGONIST ACTIVITY | J. URIACH Y COMPANIA S.A. (ES) | 2003-10-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050143391-A1 | Heterocyclic amides with alpha-4 integrin antagonist activity | ITGB4, ITGA4, ITGA1 | GPR119 789/4885CHRM4 205/4885ALDH1A1 403/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.